Junshi Biosciences announced that shareholder Shanghai Tanying reduced its stake by 20.53 million shares through block trades, accounting for 2% of the company's total share capital, with a total reduction amount of 707 million yuan. In the first quarter of 2026, Junshi Biosciences achieved revenue of 726 million yuan, with a net loss attributable to the parent company of 20.56 million yuan.
Shanghai Junshi Biosciences Co LtdShareholder Shanghai Tanying reduced its stake by 20.53 million shares, cashing out 707 million yuan, indicating selling pressure.
